Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer

An overview

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Viruses have adapted through millennia of evolution to effectively invade and lyse cells through diverse mechanisms. Strains of the attenuated measles virus Edmonston (MV-Edm) vaccine lineage can preferentially infect and destroy cancerous cells while sparing the surrounding tissues. This specificity is predominantly due to overexpression of the measles virus receptor CD46 in tumor cells. To facilitate in vivo monitoring of viral gene expression and replication, these oncolytic strains have been engineered to either express soluble marker peptides, such as the human carcinoembryonic antigen (CEA; MV-CEA virus), or genes that facilitate imaging and therapy, such as the human thyroidal sodium iodide symporter (NIS) gene (MV-NIS). Preclinical efficacy and safety data for engineered oncolytic MV-Edm derivatives that led to their clinical translation are discussed in this review, and an overview of the early experience in three ongoing clinical trials of patients with ovarian cancer, glioblastoma multiforme and multiple myeloma is provided. The information obtained from these ongoing trials will guide the future clinical application and further development of MV strains as anticancer agents.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume11
Issue number1
StatePublished - Feb 2009

Fingerprint

Oncolytic Viruses
Measles virus
Viruses
Virus Receptors
Neoplasms
Viral Genes
Carcinoembryonic Antigen
Gene Expression Profiling
Glioblastoma
Multiple Myeloma
Antineoplastic Agents
Ovarian Neoplasms
Genes
Therapeutics
Vaccines
Clinical Trials
Safety
Peptides

Keywords

  • Brain tumor
  • Clinical trial
  • Measles virus
  • Multiple myeloma
  • Ovarian cancer
  • Virotherapy

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Pharmacology

Cite this

@article{27a2b971be624e458f20effd76c09110,
title = "Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview",
abstract = "Viruses have adapted through millennia of evolution to effectively invade and lyse cells through diverse mechanisms. Strains of the attenuated measles virus Edmonston (MV-Edm) vaccine lineage can preferentially infect and destroy cancerous cells while sparing the surrounding tissues. This specificity is predominantly due to overexpression of the measles virus receptor CD46 in tumor cells. To facilitate in vivo monitoring of viral gene expression and replication, these oncolytic strains have been engineered to either express soluble marker peptides, such as the human carcinoembryonic antigen (CEA; MV-CEA virus), or genes that facilitate imaging and therapy, such as the human thyroidal sodium iodide symporter (NIS) gene (MV-NIS). Preclinical efficacy and safety data for engineered oncolytic MV-Edm derivatives that led to their clinical translation are discussed in this review, and an overview of the early experience in three ongoing clinical trials of patients with ovarian cancer, glioblastoma multiforme and multiple myeloma is provided. The information obtained from these ongoing trials will guide the future clinical application and further development of MV strains as anticancer agents.",
keywords = "Brain tumor, Clinical trial, Measles virus, Multiple myeloma, Ovarian cancer, Virotherapy",
author = "P. Msaouel and Angela Dispenzieri and Evanthia Galanis",
year = "2009",
month = "2",
language = "English (US)",
volume = "11",
pages = "43--53",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer

T2 - An overview

AU - Msaouel, P.

AU - Dispenzieri, Angela

AU - Galanis, Evanthia

PY - 2009/2

Y1 - 2009/2

N2 - Viruses have adapted through millennia of evolution to effectively invade and lyse cells through diverse mechanisms. Strains of the attenuated measles virus Edmonston (MV-Edm) vaccine lineage can preferentially infect and destroy cancerous cells while sparing the surrounding tissues. This specificity is predominantly due to overexpression of the measles virus receptor CD46 in tumor cells. To facilitate in vivo monitoring of viral gene expression and replication, these oncolytic strains have been engineered to either express soluble marker peptides, such as the human carcinoembryonic antigen (CEA; MV-CEA virus), or genes that facilitate imaging and therapy, such as the human thyroidal sodium iodide symporter (NIS) gene (MV-NIS). Preclinical efficacy and safety data for engineered oncolytic MV-Edm derivatives that led to their clinical translation are discussed in this review, and an overview of the early experience in three ongoing clinical trials of patients with ovarian cancer, glioblastoma multiforme and multiple myeloma is provided. The information obtained from these ongoing trials will guide the future clinical application and further development of MV strains as anticancer agents.

AB - Viruses have adapted through millennia of evolution to effectively invade and lyse cells through diverse mechanisms. Strains of the attenuated measles virus Edmonston (MV-Edm) vaccine lineage can preferentially infect and destroy cancerous cells while sparing the surrounding tissues. This specificity is predominantly due to overexpression of the measles virus receptor CD46 in tumor cells. To facilitate in vivo monitoring of viral gene expression and replication, these oncolytic strains have been engineered to either express soluble marker peptides, such as the human carcinoembryonic antigen (CEA; MV-CEA virus), or genes that facilitate imaging and therapy, such as the human thyroidal sodium iodide symporter (NIS) gene (MV-NIS). Preclinical efficacy and safety data for engineered oncolytic MV-Edm derivatives that led to their clinical translation are discussed in this review, and an overview of the early experience in three ongoing clinical trials of patients with ovarian cancer, glioblastoma multiforme and multiple myeloma is provided. The information obtained from these ongoing trials will guide the future clinical application and further development of MV strains as anticancer agents.

KW - Brain tumor

KW - Clinical trial

KW - Measles virus

KW - Multiple myeloma

KW - Ovarian cancer

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=58849107795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849107795&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 43

EP - 53

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -